Notes to the Condensed Consolidated Interim Financial Statements of the Bayer Group

Key Data by Segment

Key Data by Segment

 

 

Pharmaceuticals

 

Consumer Health

 

Crop Science

 

Animal Health

 

 

Q3 2017

Q3 2018

 

Q3 2017

Q3 2018

 

Q3 2017

Q3 2018

 

Q3 2017

Q3 2018

 

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

1

For definition see Annual Report 2017, Chapter “Alternative Performance Measures Used by the Bayer Group.”

Net sales (external)

 

4,065

4,163

 

1,320

1,297

 

2,031

3,733

 

359

304

Change1

 

−2.1%

+2.4%

 

−7.4%

−1.7%

 

−1.3%

+83.8%

 

−0.3%

−15.3%

Currency-adjusted change1

 

+2.2%

+4.5%

 

−2.9%

+2.4%

 

+2.7%

+86.8%

 

+3.6%

−13.5%

Intersegment sales

 

8

8

 

3

0

 

7

8

 

3

2

Net sales (total)

 

4,073

4,171

 

1,323

1,297

 

2,038

3,741

 

362

306

EBIT1

 

1,209

1,299

 

155

162

 

84

3,054

 

64

31

EBIT before special items1

 

1,206

1,315

 

173

153

 

205

(109)

 

72

34

EBITDA before special items1

 

1,493

1,554

 

274

248

 

307

386

 

81

44

Net cash provided by operating activities

 

1,036

928

 

200

210

 

841

1,244

 

68

99

Depreciation, amortization, impairment losses / loss reversals

 

287

239

 

102

97

 

115

501

 

9

10

Key Data by Segment

 

 

Reconciliation

 

 

 

 

 

All Other Segments

 

Corporate Functions and Consolidation

 

Group

 

 

Q3 2017

Q3 2018

 

Q3 2017

Q3 2018

 

Q3 2017

Q3 2018

 

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

1

For definition see Annual Report 2017, Chapter “Alternative Performance Measures Used by the Bayer Group.”

Net sales (external)

 

245

405

 

5

3

 

8,025

9,905

Change1

 

−6.1%

+65.3%

 

 

−2.8%

+23.4%

Currency-adjusted change1

 

−5.3%

+62.5%

 

 

+1.3%

+26.0%

Intersegment sales

 

583

620

 

(604)

(638)

 

Net sales (total)

 

828

1,025

 

(599)

(635)

 

8,025

9,905

EBIT1

 

(6)

35

 

(118)

(158)

 

1,388

4,423

EBIT before special items1

 

100

48

 

(119)

(141)

 

1,637

1,300

EBITDA before special items1

 

165

108

 

(116)

(138)

 

2,204

2,202

Net cash provided by operating activities

 

135

(795)

 

(377)

365

 

1,903

2,051

Depreciation, amortization, impairment losses / loss reversals

 

65

60

 

3

3

 

581

910

Key Data by Segment

 

 

Pharmaceuticals

 

Consumer Health

 

Crop Science

 

Animal Health

 

 

9M 2017

9M 2018

 

9M 2017

9M 2018

 

9M 2017

9M 2018

 

9M 2017

9M 2018

 

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

1

For definition see Annual Report 2017, Chapter “Alternative Performance Measures Used by the Bayer Group.”

Net sales (external)

 

12,632

12,455

 

4,463

4,119

 

7,314

9,605

 

1,249

1,171

Change1

 

+4.0%

−1.4%

 

−0.8%

−7.7%

 

−2.6%

+31.3%

 

+4.6%

−6.2%

Currency-adjusted change1

 

+4.6%

+3.4%

 

−0.8%

−0.6%

 

−3.2%

+37.4%

 

+4.2%

−0.1%

Intersegment sales

 

29

27

 

12

2

 

23

28

 

5

7

Net sales (total)

 

12,661

12,482

 

4,475

4,121

 

7,337

9,633

 

1,254

1,178

EBIT1

 

3,530

3,515

 

628

530

 

1,171

4,100

 

297

276

EBIT before special items1

 

3,683

3,588

 

670

525

 

1,424

1,278

 

305

282

EBITDA before special items1

 

4,476

4,332

 

980

817

 

1,739

2,059

 

332

311

Net cash provided by operating activities

 

2,537

2,789

 

762

531

 

1,332

2,194

 

134

200

Depreciation, amortization, impairment losses / loss reversals

 

939

787

 

320

294

 

352

789

 

27

29

Key Data by Segment

 

 

Reconciliation

 

 

 

 

 

All Other Segments

 

Corporate Functions and Consolidation

 

Group

 

 

9M 2017

9M 2018

 

9M 2017

9M 2018

 

9M 2017

9M 2018

 

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

1

For definition see Annual Report 2017, Chapter “Alternative Performance Measures Used by the Bayer Group.”

Net sales (external)

 

749

1,161

 

12

13

 

26,419

28,524

Change1

 

−2.3%

+55.0%

 

 

+1.1%

+8.0%

Currency-adjusted change1

 

−1.4%

+54.4%

 

 

+1.2%

+13.4%

Intersegment sales

 

1,759

1,839

 

(1,828)

(1,903)

 

Net sales (total)

 

2,508

3,000

 

(1,816)

(1,890)

 

26,419

28,524

EBIT1

 

14

81

 

(362)

(418)

 

5,278

8,084

EBIT before special items1

 

150

114

 

(359)

(385)

 

5,873

5,402

EBITDA before special items1

 

328

288

 

(350)

(374)

 

7,505

7,433

Net cash provided by operating activities

 

(106)

(1,014)

 

(304)

249

 

4,355

4,949

Depreciation, amortization, impairment losses / loss reversals

 

178

174

 

9

11

 

1,825

2,084

Compare to Last Year